Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Can money buy happiness? The relationship between money and well-being

  • Finding psychological insights through social media

  • How does the human brain tackle problems it did not evolve to solve?

  • Patient perceptions of physician compassion measured

  • Reviving drugs with anti-stroke potential, minus side effects

  • Intimate partners with low self-esteem stay in unhappy relationships

  • New compounds protect nervous system from the structural damage characteristic of multiple sclerosis

  • Shake it off? Not so easy for people with depression, new brain research suggests

  • Introverts prefer mountains

  • Research of plain wren duets could help further understand fundamentals of conversation

  •